YARAL Pharma will initially focus on the commercialization of IBSA Pharma’s corporate pipeline of authorized generics in the areas of pain and endocrinology and will expand its offering of high-quality products across a range of therapeutic areas.
YARAL Pharma is poised to rapidly expand its product line through its internal pipeline as well as outside partnerships.
Our portfolio focus will include a mix of oral solid dosage (OSD), complex and 505(b)2 products in select therapeutic areas including
- Pain and Inflammation
- Reproductive Medicine